MAPT and Alzheimer disease: As a proof-of-concept, we first wanted to see how [18F] JNJ-64326067 performed compared to tau PET tracers that use reference tissue for quantitation of the NFT signal as a readily implemented and tolerated protocol for clinical trials in AD [6, 15] while not burdening subjects with invasive sampling.